A Phase 2 interventional study of High-dose Xinglou Chengqi granules and Low-dose Xinglou Chengqi granules and placebo in Acute Ischemic Stroke, sponsored by Dongzhimen Hospital, Beijing. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-09-09.
Sponsored by Dongzhimen Hospital, Beijing · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Ischemic Stroke by Dongzhimen Hospital, Beijing — 6 open to participants now, 6 under way, none of them phase 3. Ischemic Stroke · Dongzhimen Hospital, Beijing.
Among the 16 studies in Ischemic Stroke by Dongzhimen Hospital, Beijing, this one is the 10th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2025, is one of 2 in phase 2, and was the 16th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →6 of the 16 studies in Ischemic Stroke by Dongzhimen Hospital, Beijing are open now, in 2 countries. Recruiting first, the newest first:
Dongzhimen Hospital, Beijing · Sites in China
Ages 18–80
Dongzhimen Hospital, Beijing · Sites in China
Ages 18+
Dongzhimen Hospital, Beijing · Sites in China
Ages 50–80 · Healthy volunteers
Dongzhimen Hospital, Beijing · Sites in China
Ages 18–80
Dongzhimen Hospital, Beijing · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 4 3
First in 2013; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 60 is below the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 456 across the 10 interventional studies, 1,000 across the 6 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Dongzhimen Hospital, Beijing is the lead sponsor of 45 studies on the registry; 19 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Ischemic Stroke by Dongzhimen Hospital, Beijing, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Ⅱa clinical trial. The purpose of this study is to preliminarily explore the optimal dosage of Xinglou Chengqi Granules in the treatment of acute ischemic stroke and to evaluate the efficacy and safety of Xinglou Chengqi Granules for acute ischemic stroke.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
16 g of Xinglou Chengqi granules will be given to participants in the high-dose group.
Drug: High-dose Xinglou Chengqi granules
8 g of Xinglou Chengqi granules and 8 g of placebo will be given to participants in the low-dose group.
Drug: Low-dose Xinglou Chengqi granules and placebo
Patients will receive orally high-dose Xinglou Chengqi granules, combined with guidelines-based standard care.
Also known as: Guidelines-based standard care
Patients will receive orally low-dose Xinglou Chengqi granules, combined with guidelines-based standard care.
Also known as: Guidelines-based standard care
The change of NIHSS score from baseline to day 14.
The change of the National Institutes of Health stroke scale (NIHSS) score from baseline to day 14 will be analyzed between groups.
Time frame: Baseline and Day 14.
The proportions of patients with mRS ≤ 2 or mRS ≤ 1.
The proportions of patients with modified Rankin Scale (mRS) ≤ 2 or mRS ≤ 1 will be analyzed between groups.
Time frame: Day 30, Day 60 and Day 90.
The change of NIHSS score
The change of NIHSS score will be analyzed at days 7, 30, 60, and 90.
Time frame: Day 7, day 30, day 60, day 90.
The proportion of patients with Barthel Index score ≥ 95 or ≥ 75.
The proportion of patients with Barthel Index score ≥ 95 or ≥ 75 will be analyzed at days 7, 14, 30, 60, and 90.
Time frame: day 7, day 14, day 30, day 60, day 90.
The change of EQ-5D score.
The change of EQ-5D score from baseline to days 7, 14, 30, 60, and 90 will be analyzed between groups.
Time frame: day 7, day 14, day 30, day 60, day 90.
The incidence of new cardiovascular events.
The incidence of new cardiovascular events will be analyzed at day 7, 14, 30, 60, and 90.
Time frame: day 7, day 14, day 30, day 60, day 90.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Oct 2025; primary completion for Sep 2026, 11 months later.
Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 11 months is below that.
Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dongzhimen Hospital, Beijing